1-methyl-3-isobutylxanthine has been researched along with Morphine Abuse in 7 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We provide evidence in support of the existence of mu* in human neuroblastoma cells, SH-SY5Y, and mu* upregulation during morphine treatment." | 3.69 | Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. ( Bilsky, EJ; Porreca, F; Sadée, W; Wang, Z, 1994) |
| "Pretreatment with clonidine (50 micrograms/kg, IP) significantly decreased the incidence of 11 out of 16 withdrawal signs." | 1.26 | Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome. ( Grant, SJ; Redmond, DE, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collier, HO | 1 |
| Cuthbert, NJ | 1 |
| Francis, DL | 1 |
| Grant, SJ | 1 |
| Redmond, DE | 1 |
| Wang, Z | 2 |
| Bilsky, EJ | 2 |
| Porreca, F | 2 |
| Sadée, W | 2 |
| Wang, D | 1 |
| Zaluzny, SG | 1 |
| Chesher, GB | 1 |
| Jackson, DM | 1 |
| Malor, R | 1 |
| Neal, BS | 1 |
| Sparber, SB | 2 |
| Bronson, ME | 1 |
7 other studies available for 1-methyl-3-isobutylxanthine and Morphine Abuse
| Article | Year |
|---|---|
Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines.
Topics: 1-Methyl-3-isobutylxanthine; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Caffeine; Huma | 1981 |
Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Behavior, Animal; Clonidine; Humans; Male; Morphine Dependence | 1982 |
Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Cell Line; Cerebral Ventricles; Cyclic AMP; Drug Tolerance; Ho | 1994 |
3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Animals; Cells, Cultured; Cyclic AMP; Drug Tolerance | 1999 |
The attenuation of delta 9-tetrahydrocannabinol and morphine of the quasi-morphine withdrawal syndrome in rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Behavior, Animal; Chlordiazepoxide; Dronabinol; Haloperidol; H | 1979 |
The serotonin2 antagonist ritanserin blocks quasi-morphine withdrawal at a time when mianserin is no longer effective.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Conditioning, Operant; Male; Mianserin; Morphine Dependence; N | 1990 |
Evidence of single dose opioid dependence in 12- to 14-day-old chicken embryos.
Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamid | 1989 |